All In Biotech

Drug Trial Radar · NCT01028924

Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers

A Randomised, 4-period, Placebo and Active-controlled, Single-dose, Change-over Trial to Evaluate the Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers

Last checked: Nov 19, 2026Latest source record: May 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Nov 2009

Primary completion

Feb 2010

Study completion Apr 2010

Sponsor

Lead sponsor
NycomedIndustry
Sponsor type
Industry
First posted
Dec 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to investigate if teduglutide has an effect on cardiac repolarisation (QT, QTc interval). Secondary objectives are the investigation of possible effects on heart rate and cardiac conduction (RR and PR intervals, QRS duration), pharmacokinetics and safety and tolerability in healthy subjects, and to determine the effect of the positive control, moxifloxacin, for sensitivity analysis. The trial will consist of a screening and a treatment phase of four treatment periods. There is a washout period of at least 7 days and 4 weeks at maximum between administrations. The expected total trial duration for the individual subject will be about 7 weeks (maximum 17) weeks.

Conditions

  • Healthy

Interventions

  • TeduglutideDrug

    subcutaneous (SC), single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ECG measurement/assessment to determine the effect of a single dose of teduglutide on cardiac repolarisation (QT, QTc interval).Time frame: until 24 h post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nycomed GmbH

    Konstanz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.